-
1
-
-
0034088992
-
Type 2 diabetes in children and adolescents
-
American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23: 381–389.
-
(2000)
Diabetes Care
, vol.23
, pp. 381-389
-
-
-
2
-
-
3042760009
-
Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop
-
Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27: 1798–1811.
-
(2004)
Diabetes Care
, vol.27
, pp. 1798-1811
-
-
Alberti, G.1
Zimmet, P.2
Shaw, J.3
Bloomgarden, Z.4
Kaufman, F.5
Silink, M.6
-
3
-
-
0029869077
-
Increased incidence of non-insulin-dependent diabetes mellitus among adolescents
-
Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996; 128: 608–615.
-
(1996)
J Pediatr
, vol.128
, pp. 608-615
-
-
Pinhas-Hamiel, O.1
Dolan, L.M.2
Daniels, S.R.3
Standiford, D.4
Khoury, P.R.5
Zeitler, P.6
-
4
-
-
1842537887
-
Type 2 diabetes in the young: the evolving epidemic
-
Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care 2004; 27: 998–1010.
-
(2004)
Diabetes Care
, vol.27
, pp. 998-1010
-
-
Bloomgarden, Z.T.1
-
5
-
-
84873519427
-
Prevalence of hyperinsulinism, type 2 diabetes mellitus and metabolic syndrome among Saudi overweight and obese pediatric patients
-
Al-Agha A, Ocheltree A, Shata N. Prevalence of hyperinsulinism, type 2 diabetes mellitus and metabolic syndrome among Saudi overweight and obese pediatric patients. Minerva Pediatr 2012; 64: 623–631.
-
(2012)
Minerva Pediatr
, vol.64
, pp. 623-631
-
-
Al-Agha, A.1
Ocheltree, A.2
Shata, N.3
-
6
-
-
84908221121
-
Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes
-
Karres J, Pratt V, Guettier JM et al. Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes. Diabetes Care 2014; 37: 2665–2667.
-
(2014)
Diabetes Care
, vol.37
, pp. 2665-2667
-
-
Karres, J.1
Pratt, V.2
Guettier, J.M.3
-
7
-
-
0038100206
-
Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents
-
Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 2003; 88: 1417–1427.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 1417-1427
-
-
Goran, M.I.1
Ball, G.D.2
Cruz, M.L.3
-
8
-
-
84873479807
-
Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents
-
Copeland KC, Silverstein J, Moore KR et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics 2013; 131: 364–382.
-
(2013)
Pediatrics
, vol.131
, pp. 364-382
-
-
Copeland, K.C.1
Silverstein, J.2
Moore, K.R.3
-
9
-
-
41649087328
-
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
-
Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145–1149.
-
(2008)
J Med Chem
, vol.51
, pp. 1145-1149
-
-
Meng, W.1
Ellsworth, B.A.2
Nirschl, A.A.3
-
10
-
-
84891878819
-
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
-
Kasichayanula S, Liu X, LaCreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014; 53: 17–27.
-
(2014)
Clin Pharmacokinet
, vol.53
, pp. 17-27
-
-
Kasichayanula, S.1
Liu, X.2
LaCreta, F.3
Griffen, S.C.4
Boulton, D.W.5
-
12
-
-
84976585919
-
-
Accessed 31 July 2015
-
European Medicines Agency. Forxiga summary of product characteristics. Available from URL: http://ec.europa.eu/health/documents/community-register/2012/20121112124487/anx_124487_en.pdf. Accessed 31 July 2015.
-
Forxiga summary of product characteristics
-
-
-
13
-
-
84974736701
-
-
Study NCT01525238. Accessed 31 July 2015
-
ClinicalTrials.gov. PK study of dapagliflozin in pediatric subjects with T2DM. Study NCT01525238. Available from URL: https://clinicaltrials.gov/ct2/show/NCT01525238. Accessed 31 July 2015.
-
PK study of dapagliflozin in pediatric subjects with T2DM
-
-
-
14
-
-
58549090937
-
-
World Health Organization Web site. Accessed 30 June 2015
-
World Health Organization/International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. World Health Organization Web site. Available from URL: http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 30 June 2015.
-
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia
-
-
-
15
-
-
75149130955
-
Diagnosis and classification of diabetes mellitus
-
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl. 1): S62–S69.
-
(2010)
Diabetes Care
, vol.33
, pp. S62-S69
-
-
-
17
-
-
84925002886
-
Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies
-
Ji QC, Xu X, Ma E et al. Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies. Anal Chem 2015; 87: 3247–3254.
-
(2015)
Anal Chem
, vol.87
, pp. 3247-3254
-
-
Ji, Q.C.1
Xu, X.2
Ma, E.3
-
18
-
-
67349275999
-
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
-
Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513–519.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 513-519
-
-
Komoroski, B.1
Vachharajani, N.2
Feng, Y.3
Li, L.4
Kornhauser, D.5
Pfister, M.6
-
19
-
-
0026499896
-
Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement
-
Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992; 55: 615S–619S.
-
(1992)
Am J Clin Nutr
, vol.55
, pp. 615S-619S
-
-
-
20
-
-
33750107067
-
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study
-
Liese AD, D'Agostino RB Jr, Hamman RF et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118: 1510–1518.
-
(2006)
Pediatrics
, vol.118
, pp. 1510-1518
-
-
Liese, A.D.1
D'Agostino, R.B.2
Hamman, R.F.3
-
21
-
-
84899869077
-
Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009
-
Dabelea D, Mayer-Davis EJ, Saydah S et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311: 1778–1786.
-
(2014)
JAMA
, vol.311
, pp. 1778-1786
-
-
Dabelea, D.1
Mayer-Davis, E.J.2
Saydah, S.3
-
22
-
-
84974720754
-
-
United States Census Bureau Web site. Accessed 3 September 2015
-
United States Census Bureau Quickfacts. United States Census Bureau Web site. Available from URL: http://quickfacts.census.gov/qfd/states/00000.html. Accessed 3 September 2015.
-
-
-
-
23
-
-
84873429530
-
Simultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
-
Boulton DW, Kasichayanula S, Keung CF et al. Simultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 2013; 75: 763–768.
-
(2013)
Br J Clin Pharmacol
, vol.75
, pp. 763-768
-
-
Boulton, D.W.1
Kasichayanula, S.2
Keung, C.F.3
-
24
-
-
79955001140
-
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
-
Miyagi SJ, Collier AC. The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos 2011; 39: 912–919.
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 912-919
-
-
Miyagi, S.J.1
Collier, A.C.2
-
25
-
-
84862702300
-
Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics
-
Miyagi SJ, Milne AM, Coughtrie MW, Collier AC. Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. Drug Metab Dispos 2012; 40: 1321–1327.
-
(2012)
Drug Metab Dispos
, vol.40
, pp. 1321-1327
-
-
Miyagi, S.J.1
Milne, A.M.2
Coughtrie, M.W.3
Collier, A.C.4
-
26
-
-
84974674472
-
Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus
-
Parkinson J, Tang W, Johansson C-C, Boulton DW, Hamrén B. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 685–692.
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 685-692
-
-
Parkinson, J.1
Tang, W.2
Johansson, C.-C.3
Boulton, D.W.4
Hamrén, B.5
|